Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADREL: Apixaban Dose Reduction in High-Risk AF
NCT02809469Phase 2Unknown
- Sponsor
- Hamilton Health Sciences
- Start
- Aug 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of apixaban in Atrial fibrillation (AFib), sponsored by Hamilton Health Sciences. Status: unknown.
02
Drugs
apixaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02809469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02809469.